Metastatic Bone Disease Treatment Market Size, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026

Metastatic Bone Disease Treatment size is expected to grow significantly from 2019 to 2025.
 

An increase in the prevalence of cancers such as breast, and prostate, and lung, that metastasize to bones are expected to propel the demand for the metastatic bone disease treatment market during the forecast period. According to the American Academy of Orthopaedic Surgeons, in the U.S., every year more than 1.2 million new cancer cases are diagnosed with cancer, and among them, about 50% of these tumors are metastatic that means it can metastasize or spread to the skeleton. The constant growth of the impact of cancer on Public Health is the key factor that drives the metastatic bone disease treatment market.
 

Stringent regulatory guidelines assuring improved product quality, favorable reimbursement scenario, surge in new drug approvals, and rise in cancer awareness programs by patient support organizations and will foster business growth. Moreover, rise in awareness about new pipeline drugs, growth in efforts of biotechnological and pharmaceutical companies to develop newer molecule are also anticipated to fuel the market revenue for metastatic bone tumor treatment over the forecast period. However, the high cost of medicines, large capital required for research and development activities, and the diverse nature of cancer are some of the key factors restricting the metastatic bone cancer treatment market.
 

The medication segment is estimated to account for significant market share in the metastatic bone cancer treatment market in 2018. The growing investment by multinational corporations in cancer research, FDA approvals for newer medicines for the patients suffering from metastatic bone tumors anticipated propelling the growth of the segment during the forecast period. Hormone therapy, chemotherapy, immunotherapy, and opiate therapy are generally prescribed treatment for metastatic bone diseases. Furthermore, enhanced awareness about personalized medicine is a key opportunity of the metastatic bone disease treatment market.
 

The breast cancer segment should witness significant growth in the metastatic bone disease treatment market during the forecast period. Breast cancer is the most common cancer that spreads to anywhere in the body, most commonly the brain, liver, lungs or bones. According to Centers for Disease Control and Prevention (CDC), in the U.S., about 245,299 cases of breast cancer in females were reordered in 2016. The growing prevalence of breast cancer is expected to propel the growth of the segment over the forecast period.
 

The hospital's segment accounts a significant share in the metastatic bone disease treatment market in 2018. The necessity of cutting-edge healthcare infrastructure for the management of metastatic cancer. Moreover, the quality of care provided, and favorable reimbursement facilities in hospitals for cancer treatment is also expected to spur the growth of the segment in the market.
 

North America accounts significant revenue share in the metastatic bone disease treatment market 2018. Due to the augmented prevalence of cancer and improved investment in R&D and launch of numerous new drugs are anticipated to support the growth of the North America market. Moreover, reimbursement plans are very high in North America, which will additionally fuel the growth of the metastatic bone disease treatment market over the forecast period.
 

Some of the major players operating in the metastatic bone disease treatment industry include Merck, Amgen, F. Hoffmann-La Roche, Eli Lilly and Company, Novartis, Bayer, Fresenius Kabi, Boston Scientific Corporation, Medtronic, and C. R. Bard. The market for metastatic bone diseases is characterized by growth in new product launches, a large number of strategic partnerships and acquisitions, and increased dominance of the leading players. For instance, in February 2018 Roche has announced the acquisition of Flatiron Health to fast-track industry-wide expansion and delivery of innovative medicines for patients with cancer. The acquisition will allow influencing their combined skill to advance the use of real-world evidence to set new business standards for cancer research and development, and that expected to generate immense opportunity for the growth of the market globally.  
 

Metastatic Bone Disease Treatment Market By Treatment, 2014-2025 (USD Million)

• Medication
  • Chemotherapy
  • Hormone Therapy
  • Bisphosphonates
  • Opiate Therapy
  • Immunotherapy
• Radiation Therapy
• Surgical Intervention
• Tumor Ablation Therapy

Metastatic Bone Disease Treatment Market By Origin of Metastasis, 2014-2025 (USD Million)

• Breast
• Lung
• Thyroid
• Kidney
• Prostate
• Others

Metastatic Bone Disease Treatment Market By End-user, 2014-2025 (USD Million)

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
• Latin America
  • Mexico
  • Brazil
• Middle East and Africa
  • Saudi Arabia
  • South Africa

Company Profiles:

• Merck
• Amgen
• F. Hoffmann-La Roche
• Eli Lilly and Company
• Novartis
• Bayer
• Fresenius Kabi
• Boston Scientific Corporation
• Medtronic
• C. R. Bard

What Information does this report contain?